Published in Nat Rev Urol on December 08, 2009
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev (2010) 1.41
Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem (2012) 1.14
Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) (2011) 0.99
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res (2011) 0.89
A possible predictive marker of progression for hepatocellular carcinoma. Oncol Lett (2011) 0.87
The role of functional foods, nutraceuticals, and food supplements in intestinal health. Nutrients (2010) 0.84
Current concepts and prospects of herbal nutraceutical: A review. J Adv Pharm Technol Res (2013) 0.81
Novel Lignan and stilbenoid mixture shows anticarcinogenic efficacy in preclinical PC-3M-luc2 prostate cancer model. PLoS One (2014) 0.77
Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prev Res (Phila) (2015) 0.77
Prevention strategies in prostate cancer. Curr Oncol (2010) 0.76
Role of diet in prostate cancer: the epigenetic link. Oncogene (2014) 0.76
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA (2015) 0.75
Correlation between Oxidative Stress, Nutrition, and Cancer Initiation. Int J Mol Sci (2017) 0.75
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (1998) 4.72
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys (1989) 3.33
Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst (1995) 3.24
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer (1991) 3.14
Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res (2005) 3.13
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control (2004) 3.10
An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer (2002) 3.07
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 3.04
Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol (2006) 2.99
Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev (1993) 2.82
Vitamin D for cancer prevention: global perspective. Ann Epidemiol (2009) 2.61
The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst (2007) 2.56
A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst (2002) 2.49
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst (2006) 2.48
Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol (2007) 2.38
Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res (1999) 2.30
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control (2000) 2.24
Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, cause. JAMA (2008) 2.24
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med (2007) 2.20
A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res (1989) 2.18
A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int (2003) 2.10
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res (1990) 2.00
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer (1992) 1.96
Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer (1989) 1.91
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer (2004) 1.80
Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev (2004) 1.72
Dietary agents for chemoprevention of prostate cancer. Cancer Lett (2008) 1.72
Lycopene: modes of action to promote prostate health. Arch Biochem Biophys (2004) 1.65
The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev (2004) 1.65
Residential sunlight exposure is associated with a decreased risk of prostate cancer. J Steroid Biochem Mol Biol (2004) 1.64
Geographic trends in prostate cancer mortality: an application of spatial smoothers and the need for adjustment. Ann Epidemiol (1997) 1.58
Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr (2009) 1.57
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst (2001) 1.47
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States) Cancer Causes Control (1998) 1.46
Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer (2008) 1.45
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2001) 1.43
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Vitamin D and the epidemiology of prostate cancer. Semin Dial (2005) 1.41
Response of hormone refractory prostate cancer to lycopene. J Urol (2001) 1.40
Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr (2007) 1.40
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev (1998) 1.39
Nutraceutical--definition and introduction. AAPS PharmSci (2003) 1.38
Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev (1999) 1.37
UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control (2006) 1.37
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev (1996) 1.36
Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J Nutr (1992) 1.35
Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2007) 1.34
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol (2004) 1.32
Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Am J Clin Nutr (1997) 1.31
A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control (2004) 1.28
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem (2003) 1.25
Soy isoflavones in the treatment of prostate cancer. Nutr Cancer (2003) 1.24
A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol (2005) 1.23
Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev (2007) 1.21
The specific role of isoflavones in reducing prostate cancer risk. Prostate (2004) 1.16
A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.12
No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer (2006) 1.08
Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol (1999) 1.07
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol (2005) 1.06
Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer. Mol Biotechnol (2007) 1.06
Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer (2007) 1.04
Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer (1996) 1.01
Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology (2004) 1.00
Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology (2004) 0.99
Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer (2008) 0.97
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology (2006) 0.97
Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer (1999) 0.96
Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer (2005) 0.95
Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res (2003) 0.95
Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Ann Epidemiol (2009) 0.94
Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2004) 0.93
Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J Urol (2008) 0.92
The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol (2001) 0.92
Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer (2009) 0.89
Soy, isoflavones, and prostate cancer. Mol Nutr Food Res (2009) 0.88
Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer (2003) 0.88
Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol (2004) 0.87
Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep (2008) 0.86
A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology (2007) 0.83
Mediterranean diet and cancer. Eur J Clin Nutr (1989) 0.83
Chemoprevention of prostate cancer: what can be recommended to patients? Curr Urol Rep (2009) 0.83
Observational versus randomised trial evidence. Lancet (2004) 0.82
Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res (2003) 0.81
Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer. J Nutr (2007) 0.80
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. J Urol (2009) 0.78
Age-adjusted mortality rate and regional distribution for prostatic carcinoma in Italy between 1969 and 1978. Prostate (1982) 0.76
The promiscuous receptor. BJU Int (2009) 0.76
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Therapeutic options following orchiectomy for stage I seminoma. Oncology (Williston Park) (2009) 2.67
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Longer wait times increase overall mortality in patients with bladder cancer. J Urol (2009) 2.05
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
Is there an optimal comorbidity index for prostate cancer? Cancer (2008) 1.80
Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation. Urology (2009) 1.78
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol (2010) 1.63
Long-term outcomes of external sphincterotomy in a spinal injured population. J Urol (2008) 1.57
Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57
Population based survival data on urachal tumors. J Urol (2006) 1.55
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Vulvar hematoma secondary to spontaneous rupture of the internal iliac artery: clinical review. Am J Obstet Gynecol (2009) 1.52
Higher surgeon and hospital volume improves long-term survival after radical cystectomy. Cancer (2013) 1.52
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 1.50
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Metaplastic conditions of the bladder. BJU Int (2013) 1.47
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Globalization of continuing professional development by journal clubs via microblogging: a systematic review. J Med Internet Res (2015) 1.44
Demographic analysis: an update of randomized controlled studies in prostatic oncology. Can Urol Assoc J (2011) 1.42
The emerging use of Twitter by urological journals. BJU Int (2014) 1.42
Renal colic: current protocols for emergency presentations. Eur J Emerg Med (2016) 1.42
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41
Manual bladder washouts for urinary clot retention: a survey of knowledge among healthcare workers. Can J Urol (2015) 1.40
A marriage of inconvenience. Med J Aust (2005) 1.39
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med (2006) 1.38
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int (2014) 1.32
Is there age bias in the treatment of localized prostate carcinoma? Cancer (2004) 1.29
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol (2010) 1.25
The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int (2015) 1.19
The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int (2013) 1.19
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study. Can Urol Assoc J (2011) 1.17
The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol (2007) 1.16
The social media revolution is changing the conference experience: analytics and trends from eight international meetings. BJU Int (2015) 1.14
Transperineal biopsy of the prostate--is this the future? Nat Rev Urol (2013) 1.14
Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol (2002) 1.13
Organ-sparing approaches for testicular masses. Nat Rev Urol (2010) 1.12
Diagnosis of bone metastases in urological malignancies--an update. Urology (2010) 1.11
Gene expression profiling of localized prostate cancer: getting answers to the questions that really matter. J Clin Oncol (2013) 1.08
Urologists in cyberspace: A review of the quality of health information from American urologists' websites using three validated tools. Can Urol Assoc J (2013) 1.07
Laparoscopic lens fogging: a review of etiology and methods to maintain a clear visual field. J Endourol (2010) 1.07
Consumerism and its impact on robotic-assisted radical prostatectomy. BJU Int (2011) 1.05
Metachronous metastasis to the penis from carcinoma of the rectum. Int J Urol (2006) 1.05
Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res (2002) 1.04
Antioxidants block prostate cancer in lady transgenic mice. Cancer Res (2004) 1.03
The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol (2011) 1.03
DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest (2010) 1.01
Functional imaging of intratumoral hypoxia. Mol Imaging Biol (2004) 1.01
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol (2012) 1.00
Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol (2010) 1.00
Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol (2009) 1.00
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int (2011) 0.98
A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev Res (Phila) (2009) 0.96
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology (2009) 0.95
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther (2008) 0.94
Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol (2010) 0.94
Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol (2011) 0.93
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int (2012) 0.91
The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J (2009) 0.91
Placenta percreta with urinary tract involvement: the case for a multidisciplinary approach. Urology (2009) 0.91
Prevention and management of TURP-related hemorrhage. Nat Rev Urol (2011) 0.90
Oral contraceptive use is associated with prostate cancer: an ecological study. BMJ Open (2011) 0.90
Penile lichen sclerosus (balanitis xerotica obliterans). BJU Int (2011) 0.90
Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol (2002) 0.90
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol (2009) 0.90
Varied definitions of hospital volume did not alter the conclusions of volume-outcome analyses. J Clin Epidemiol (2008) 0.89
Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study. Radiology (2012) 0.89
An analysis of world media reporting of two recent large randomized prospective trials investigating screening for prostate cancer. BJU Int (2011) 0.88
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem (2013) 0.88
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics (2012) 0.88
MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol (2010) 0.88
Focal laser ablation for localized prostate cancer. J Endourol (2010) 0.88
An update on chemoprevention strategies in prostate cancer for 2006. Curr Opin Urol (2006) 0.88
Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. BJU Int (2013) 0.87
An investigation of the basic physics of irrigation in urology and the role of automated pump irrigation in cystoscopy. ScientificWorldJournal (2012) 0.87
Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int (2006) 0.85
Orthotopic bladder substitution (Neobladder): part II: postoperative complications, management, and long-term follow-up. J Wound Ostomy Continence Nurs (2013) 0.85
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol (2010) 0.85
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int (2012) 0.85